Sorrento Therapeutics records $13.27 million net loss for April

By Sarah Lizee

Olympia, Wash., June 15 – Sorrento Therapeutics, Inc. reported a $13.27 million net loss for April on $40,013 of gross income/sales, according to its monthly operating report filed Wednesday with the U.S. Bankruptcy Court for the Southern District of Texas.

The cash balance at the end of April was $34.45 million.

The biopharmaceutical company is based in San Diego. The company filed bankruptcy on Feb. 13 under Chapter 11 case number 23-90085.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.